The safety of dupilumab in older adults is crucial due to comorbidities and polypharmacy, but this group is often underrepresented in clinical trials. We herein report a real-world experience with dupilumab in treating 138 atopic dermatitis in patients aged 60 years and older. Our study demonstrated that dupilumab has excellent safety outcomes and consistent improvements across all clinical scores.
Three-year observational study on the long-term efficacy and safety of dupilumab in elderly patients with severe atopic dermatitis / A. Chiei-Gallo, F. Barei, P. Calzari, A. Pisapia, A.V. Marzano, S.M. Ferrucci. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 1365-2230. - 50:3(2025), pp. 659-662. [10.1093/ced/llae420]
Three-year observational study on the long-term efficacy and safety of dupilumab in elderly patients with severe atopic dermatitis
A. Chiei-GalloPrimo
;F. Barei
;P. Calzari;A. Pisapia;A.V. Marzano;
2025
Abstract
The safety of dupilumab in older adults is crucial due to comorbidities and polypharmacy, but this group is often underrepresented in clinical trials. We herein report a real-world experience with dupilumab in treating 138 atopic dermatitis in patients aged 60 years and older. Our study demonstrated that dupilumab has excellent safety outcomes and consistent improvements across all clinical scores.
| File | Dimensione | Formato | |
|---|---|---|---|
|
llae420.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
823.34 kB
Formato
Adobe PDF
|
823.34 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
